Related Experiment Video
Updated: Apr 19, 2026

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
Published on: June 15, 2016
The transcriptional repressor ZBTB4 regulates EZH2 through a MicroRNA-ZBTB4-specificity protein signaling axis
Won Seok Yang1, Gayathri Chadalapaka2, Sung-Gook Cho3
1Department of Environmental Health, University of Cincinnati, College of Medicine, 3223 Eden Ave., Cincinnati, OH 45267.
Abstract:
ZBTB4 is a transcriptional repressor and examination of publically-available microarray data sets demonstrated an inverse relationship in the prognostic value and expression of ZBTB4 and the histone methyltransferase EZH2 in tumors from breast cancer patients. The possibility of functional interactions between EZH2 and ZBTB4 was investigated in breast cancer cells and the results showed that EZH2 is directly suppressed by ZBTB4 which in turn is regulated (suppressed) by miR-106b and other paralogues from the miR-17-92, miR-106b-25 and miR-106a-363 clusters that are highly expressed in breast and other tumors. ZBTB4 also acts a suppressor of specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4, and RNA interference studies show that Sp proteins are required for EZH2 expression. The prediction analysis results from breast cancer patient array data sets confirm an association of Sp1-dependent EZH2 gene signature with decreased survival of breast cancer patients. Disruption of oncogenic miR-ZBTB4 signaling axis by anticancer agent such as betulinic acid that induce down-regulation of Sp proteins in breast cancer cells resulted in inhibition of tumor growth and colonization of breast cancer cells in a mouse model. Thus, EZH2 is reciprocally regulated by a novel signaling network consisting of Sp proteins, oncogenic miRs and ZBTB4, and modulation of this gene network is a novel therapeutic approach for treatment of breast cancer and possibly other cancers.
Insights
ZBTB4, a transcriptional repressor, and EZH2 show an inverse relationship in breast cancer. Targeting the oncogenic miR-ZBTB4-Sp-EZH2 axis with agents like betulinic acid inhibits tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Gene Regulation
Background:
- ZBTB4 acts as a transcriptional repressor.
- An inverse correlation exists between ZBTB4 and EZH2 expression in breast cancer patients.
- EZH2 is a histone methyltransferase implicated in cancer progression.
Purpose of the Study:
- To investigate the functional interaction between EZH2 and ZBTB4 in breast cancer.
- To elucidate the regulatory network involving ZBTB4, EZH2, microRNAs, and Sp transcription factors.
- To evaluate the therapeutic potential of targeting this network in breast cancer.
Main Methods:
- Analysis of public microarray data from breast cancer patients.
- Investigation of gene and protein expression in breast cancer cell lines.
- RNA interference studies to assess the role of Sp proteins.
- In vivo studies using a mouse model to evaluate therapeutic efficacy.
Main Results:
- ZBTB4 directly suppresses EZH2 expression.
- miR-106b and related microRNAs regulate ZBTB4.
- Sp proteins (Sp1, Sp3, Sp4) are required for EZH2 expression and are suppressed by ZBTB4.
- An Sp1-dependent EZH2 gene signature is associated with decreased patient survival.
- Betulinic acid disrupts the miR-ZBTB4 signaling axis, down-regulates Sp proteins, and inhibits tumor growth and colonization in mice.
Conclusions:
- EZH2 is reciprocally regulated by a novel network of Sp proteins, oncogenic microRNAs, and ZBTB4.
- Modulation of this gene network represents a potential therapeutic strategy for breast cancer.
- This signaling network may also be relevant for the treatment of other cancers.
More Related Videos
Related Concept Videos
Master Transcription Regulators
Master Transcription Regulators
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Co-activators and Co-repressors
RNA Polymerase II Accessory Proteins
MicroRNAs

